Atrial Fibrillation Clinical Trials in Houston, Texas

6 studies are recruiting for atrial fibrillation in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

   REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in parti…

   Stage

   Phase 3

   Ages

   22 to 85

   Site

   Baylor College of Medicine, Houston, Texas

   Locations

   93 in total

   Run by

   Johns Hopkins University

   See if you can join NCT05836987 on ClinicalTrials.gov

2. Tracking Results of Ablations to Combat AF Registry Generation 2

   The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct open concomitant and/or hybrid ablation, and management of the LAA concomitant to a cardiac ablation.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Michael E. DeBakey VAMC - Houston, Houston, Texas

   Locations

   29 in total

   Run by

   AtriCure, Inc.

   See if you can join NCT05111015 on ClinicalTrials.gov

3. Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

   The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated c…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Baylor College of Medicine, Houston, Texas

   Locations

   106 in total

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT04045665 on ClinicalTrials.gov

4. Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

   Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in b…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Houston Methodist Hospital, Houston, Texas

   Locations

   187 in total

   Run by

   Yale University

   See if you can join NCT03907046 on ClinicalTrials.gov

5. Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

   Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient atrial fibrillation occurring transiently with stress and additional stroke risk factors.

   Stage

   Phase 4

   Ages

   55 and older

   Site

   Mcgovern Medical School at University of Texas, Houston, Texas

   Locations

   105 in total

   Run by

   Population Health Research Institute

   See if you can join NCT03968393 on ClinicalTrials.gov

6. Identification of Genomic Predictors of Adverse Events After Cardiac Surgery

   This study aims to identify genetic causes of adverse events after cardiac surgery, such as atrial fibrillation, myocardial infarction, renal dysfunction and heart failure. Patients undergoing heart surgery at Brigham and Women's Hospital and Texas Heart Institute are eligible to participate.

   Stage

   Not phased

   Ages

   20 to 90

   Site

   Department Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas

   Locations

   3 in total

   Run by

   Brigham and Women's Hospital

   See if you can join NCT01258231 on ClinicalTrials.gov